Corcept Therapeutics (CORT)
(Real Time Quote from BATS)
$33.25 USD
-1.23 (-3.57%)
Updated Jun 7, 2024 02:08 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 21 - 40 ( 224 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CORT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Multiple Clinical Data Readouts Expected in 2024; PT Up To $34; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Korlym Revenue Higher Than Expected; Key Catalysts Center on Relacorilant; New $32 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Miricorilant NASH Data Could be the Next Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Cushing?s Syndrome Franchise to Remain Strong in 2023 and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S